All questions
Safety: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer 14 questions · 4 sources
Safety questions that apply to every indication of Kisqali are on Kisqali (ribociclib), all indications: Safety .
Side effects What are the most common side effects of Kisqali in metastatic breast cancer? Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7
“In addition, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to
KISQALI in 1065 patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-3, MONALEESA-
7), of whom 76% were exposed for 6 months or longer, and 62% were exposed for greater than one year. The most common
(≥ 20%) adverse reactions, including laboratory abnormalities, were leukocytes decreased (95%), neutrophils decreased
(93%), hemoglobin decreased (68%), lymphocytes decreased (66%), aspartate aminotransferase increased (55%), gamma-
glutamyl transferase increased (53%), alanine aminotransferase increased (52%), infections (47%), nausea (47%), creatinine
increased (42%), fatigue (35%), platelets decreased (34%), diarrhea (33%), vomiting (29%), headache (27%), constipation
(25%), alopecia (25%), cough (24%), rash (24%), back pain (24%), and glucose serum decreased (20%).” (opens the source at this quote in a new tab) Copy Flag
What are the side effects of Kisqali plus letrozole (MONALEESA-2)? Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)
“The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory
abnormalities, were neutrophils decreased, leukocytes decreased, hemoglobin decreased, nausea, lymphocytes decreased,
alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, diarrhea, alopecia, vomiting, platelets
decreased, constipation, headache, and back pain.” (opens the source at this quote in a new tab) Copy Flag
What are the side effects of Kisqali plus fulvestrant (MONALEESA-3)? Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)
“The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory
abnormalities, were leukocytes decreased, neutrophils decreased, lymphocytes decreased, creatinine increased, hemoglobin
decreased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, nausea, alanine aminotransferase
increased, infections, platelets decreased, diarrhea, vomiting, constipation, glucose serum decreased, cough, rash, and
pruritus.” (opens the source at this quote in a new tab) Copy Flag
What are the side effects of Kisqali in premenopausal women (MONALEESA-7)? Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)
“The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory
abnormalities, were leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, gamma-
glutamyl transferase increased, aspartate aminotransferase increased, infections, arthralgia, alanine aminotransferase
increased, nausea, platelets decreased, and alopecia.” (opens the source at this quote in a new tab) Copy Flag
What serious or fatal side effects occurred with Kisqali in MONALEESA trials? “Serious adverse reactions occurred in 21% of patients who received KISQALI plus letrozole. Serious adverse reactions in
≥ 1% of patients receiving KISQALI plus letrozole included abdominal pain (1.5%), vomiting (1.5%), constipation (1.2%),
nausea (1.2%), anemia (1.2%), febrile neutropenia (1.2%), dyspnea (1.2%), and alanine aminotransferase increased (1.2%).
Fatal adverse reactions occurred in 1.8% of patients who received KISQALI. Fatal adverse reactions in ≥ 0.1% of patients
receiving KISQALI included acute respiratory failure (0.6%), acute myocardial infarction, sudden death (with Grade 3
hypokalemia and Grade 2 QT prolongation), unknown cause, and pneumonia (0.3% each).” (opens the source at this quote in a new tab) Copy Flag
“Serious adverse reactions occurred in 29% of patients who received KISQALI plus fulvestrant. Serious adverse reactions in
≥ 1% of patients receiving KISQALI plus fulvestrant included pneumonia (1.9%), nausea (1.4%), vomiting (1.4%), anemia
(1.2%), dyspnea (1.2%), neutropenia (1.2%). One case (0.2%) of fatal adverse reaction (pneumonia) occurred in patients
who received KISQALI plus fulvestrant.
Fatal adverse reactions occurred in 1.2% of patients who received KISQALI. Fatal adverse reactions in ≥ 0.1% of patients
receiving KISQALI included cardiac failure, ventricular arrhythmia, pneumonia, acute respiratory distress, pulmonary
embolism, and hemorrhagic shock (0.2% each).” (opens the source at this quote in a new tab) Copy Flag
Note: The three passages are from the MONALEESA-2 (with letrozole), MONALEESA-7 (with a nonsteroidal aromatase inhibitor and goserelin), and MONALEESA-3 (with fulvestrant) safety sections of the Prescribing Information, in that order.
How often did patients stop Kisqali for side effects in metastatic breast cancer trials? Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.
How often was the Kisqali dose reduced for side effects in MONALEESA trials? Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.
Warnings Can Kisqali cause lung problems (ILD or pneumonitis)? Note: The last passage is the dose adjustment guidance for ILD/pneumonitis on the dose adjustments page of the Kisqali HCP site.
Does Kisqali cause QT prolongation or heart rhythm problems? How common is QT prolongation with Kisqali in each MONALEESA trial? Can Kisqali cause liver problems? Does Kisqali cause neutropenia (low white blood cell counts)? Monitoring What lab tests and monitoring are needed with Kisqali? What tests are needed before starting Kisqali?